Open Innovation Opportunity

Project Proposal

We have developed a serological test for autoimmune diseases, including Scleroderma and Lupus, which measures type I IFN activity. For Scleroderma we have seen this is linked to progression of the disease. This test could be used along side ANA testing, to stratify for disease worsening and as a companion diagnostic -stratifying for patients into targeted IFN therapies, and assisting with showing response.

International experts required to develop the following;

1. Improvement of the test for adoption within CROs and/or NHS
2. Access/assessment in additional cohorts of type I IFN linked diseases with longitudinal serological samples and clinical mapping
3. Health economists
4. Clinical experts in relevant diseases
5. IVD experts
6. Statistician